Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort
Top Cited Papers
- 2 December 2005
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 19 (18) , 2109-2116
- https://doi.org/10.1097/01.aids.0000194808.20035.c1
Abstract
Objectives: To determine the long-term incidence of tuberculosis (TB) and associated risk factors among individuals receiving HAART in South Africa. Design: Prospective cohort study. Methods: Microbiologically or histologically confirmed incident TB was identified in a hospital-based cohort of 346 patients receiving HAART between 1996 and 2005 in Cape Town. Results: The TB incidence density rate was 3.5/100 person-years in the first year and significantly decreased during follow-up, reaching 1.01/100 person-years in the fifth year (P = 0.002 for trend). TB incidence during the study was highest among patients with baseline CD4 cell counts < 100 cells/μl and those with World Health Organization (WHO) clinical stage 3 or 4 disease (5.71 and 3.88/100 person-years, respectively). Risk of TB was independently associated with CD4 cell count < 100 cells/μl (adjusted risk ratio [ARR], 2.38; 95% confidence interval (CI), 1.01–5.60; P = 0.04), WHO stage 3 or 4 disease (ARR, 3.60; 95% CI, 1.32–9.80; P = 0.01) and age < 33 years (ARR, 2.86; 95% CI, 1.29–6.34; P = 0.01). Risk of TB was not independently associated with plasma viral load, previous history of TB, low socioeconomic status or sex. Despite similar virological responses to HAART, blood CD4 cell count increases were much smaller among patients who developed TB than among those who remained free of TB. Conclusions: Incidence of TB continues to decrease during the first 5 years of HAART and so HAART may contribute more to TB control in low-income countries than was previously estimated from short-term follow-up. Patients with advanced pretreatment immunodeficiency had persistently increased risk of TB during HAART; this may reflect limited capacity for immune restoration among such patients.Keywords
This publication has 30 references indexed in Scilit:
- Tuberculosis in HIV‐infected persons in the context of wide availability of highly active antiretroviral therapyEuropean Respiratory Journal, 2004
- Initiating highly active antiretroviral therapy in sub-Saharan AfricaAIDS, 2004
- Discontinuation of Maintenance Therapy for Cryptococcal Meningitis in Patients with AIDS Treated with Highly Active Antiretroviral Therapy: An International Observational StudyClinical Infectious Diseases, 2004
- Incomplete Immune Reconstitution after Initiation of Highly Active Antiretroviral Therapy in Human Immunodeficiency Virus–Infected Patients with Severe CD4+Cell DepletionThe Journal of Infectious Diseases, 2003
- Antiretroviral Drugs for Tuberculosis Control in the Era of HIV/AIDSScience, 2003
- Nadir CD4+ T-cell count and numbers of CD28+ CD4+ T-cells predict functional responses to immunizations in chronic HIV-1 infectionAIDS, 2003
- Human Immunodeficiency Virus–1 RNA Levels and CD4 Lymphocyte Counts, during Treatment for Active Tuberculosis, in South African PatientsThe Journal of Infectious Diseases, 2003
- Reduced Risk of Tuberculosis among Brazilian Patients with Advanced Human Immunodeficiency Virus Infection Treated with Highly Active Antiretroviral TherapyClinical Infectious Diseases, 2002
- Discontinuation of Secondary Prophylaxis againstPneumocystis cariniiPneumonia in Patients with HIV Infection Who Have a Response to Antiretroviral TherapyNew England Journal of Medicine, 2001
- Risk Factors for Developing Tuberculosis in HIV-1–Infected Adults From Communities With a Low or Very High Incidence of TuberculosisJAIDS Journal of Acquired Immune Deficiency Syndromes, 2000